Log in

BIONi010-C-3 Gene-edited iPSC line

Donor information

Donor karyotype:46, XY

Disease status


Disease: normal

Disease/phenotype related genetic modifications

Disease: Alzheimer's disease
Type of modification: Gene knock-out
Gene: ApoE
Chromosome location: 19q13.32
Delivery method: CRISPR-associated (CRISPR/Cas) System
Description: The ApoE gene is knocked out in this line; deletion of the ApoE gene by insertion of a frame shift in exon 1. The target locus has been mutated.

General information

Cell line name:BIONi010-C-3
Cell line alternative names:BIONi010-C ApoE KO #KO30 P30
Biosamples ID:SAMEA4342740
hPSCreg name:BIONi010-C-3
Derivation country:Denmark

Related lines

Derived from: BIONi010-C
All subclones of BIONi010-C: BIONi010-C-10, BIONi010-C-11, BIONi010-C-12, BIONi010-C-13, BIONi010-C-15, BIONi010-C-17, BIONi010-C-18, BIONi010-C-19, BIONi010-C-2, BIONi010-C-24, BIONi010-C-25, BIONi010-C-3, BIONi010-C-4, BIONi010-C-5, BIONi010-C-6, BIONi010-C-7, BIONi010-C-8, BIONi010-C-9
From the same donor: BIONi010-A, BIONi010-B
Timepoint: Confluence
Magnification: x10
Timepoint: Confluence
Magnification: x4
This line is part of a set of isogenic APOE lines based on the iPS cell line BIONi010-C. The set comprises the following APOE genotypes: • BIONi010-C-6 (APOE 2/2) • BIONi010-C-2 (APOE 3/3) • BIONi010-C (APOE 3/4) • BIONi010-C-4 (APOE 4/4) • BIONi010-C-3 (APOE KO) A DNA SNP array revealed no larger chromosomal aberrations to be reported. An unsignificant duplication of 1,4Mbp was found on Chr22 in q11.23. This duplication was found in all isogenic lines generated from BIONi010-C as well as BIONi010-C. Other isogenic ApoE cell line cohorts are also available, generated from BIONi37-A, UKBi011-A and STBci006-A.
At European Collection of Authenticated Cell Cultures (ECACC)
In stock
Cell Line Information Pack
A Cell Line Information Pack (CLIP) is created to communicate cell line specific information relating to restrictions on use to a user accessing cell lines from EBiSC. A CLIP contains information about a cell line including any specific third party obligations (TPOs) relating to, for example, intellectual property (IP) or the donor consent which affect the use of the cell line.